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Early-onset breast cancer - histopathological and
prognostic considerations
J Kollias, CW Elston, 10 Ellis, JFR Robertson and RW Blamey
Nottingham City Hospital, Hucknall Road, Nottingham NG5 1 PB, UK
Summary Young age at diagnosis is claimed to be a prognostic factor in the natural history of breast cancer. Of 2879 patients aged < 70 years
treated for primary operable breast cancer (< 5 cm diameter) at Nottingham City Hospital between 1973 and 1993, 120 were less than
35 years of age at diagnosis. Histopathological and prognostic variables were compared between patients aged < 35, 35-50 and 51-70
years. A significant reduction in metastasis disease-free survival and actuarial survival was seen in breast cancer patients aged < 35 years
compared with the two older age groups. Patients aged < 35 years at diagnosis presented more frequently with high-grade cancers and
vascular invasion. No differences were seen fortumour size or lymph node stage. The Nottingham Prognostic Index (NPI) was used to stratify
cancers in each age group. Because of the tendency to high grade, a greater percentage of patients aged < 35 years fell into the poor-
prognosis group. Within each prognostic group, no difference in actuarial survival was seen between age groups. The association of young
age at diagnosis with a worse prognosis in this series is explained by a higher proportion of poorly differentiated cancers; age itself had no
influence on the prognosis of the individual.
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There is a general perception that young age at diagnosis ofbreast
cancer is associated with a poor prognosis (Earley et al, 1969;
Brightmore et al, 1970; Noyes et al, 1982; Adami et al, 1986;
Host and Lund, 1986; Ries et al, 1991; Sant et al, 1991; De La
Rochefordiere et al, 1993; Bonnier et al, 1995). However, other
studies suggest that patients who develop breast cancer at a young
age have a similar prognosis to older patients and that manage-
ment of young breast cancer patients is best dictated by standard
clinical andhistopathological criteria (Birks etal, 1973; Gogas and
Skalkeas, 1975; Wallgren et al, 1977; Rosen et al, 1984;
Backhouse et al, 1987; Barchielli et al, 1994).
The aims of this study were to assess prognostic factors and
survival in young women diagnosed with operable primary inva-
sive breast cancer and to compare these with cancers in older
patients.
PATIENTS AND METHODS
Between 1973 and 1993, 2879 patients aged < 70 years underwent
surgery for primary operable breast cancer (< 5 cm clinical diam-
eter). Patients were categorized according to three defined age
groups. One hundred and twenty (4%) were aged < 35 years at
diagnosis (age group I), 1003 (35%) were aged 35-50 years (age
group II) and 1756 (61%) were aged 51-70 years (age group III).
Of patients aged < 35 years at the time of diagnosis, three were
aged < 25 (2%), 32 were aged 25-29 (26%) and 85 were aged
30-34 years (72%).
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Surgical treatment
Surgery consisted of breast conservation (lumpectomy + intact
breast radiation) or mastectomy with node sampling for invasive
cancers. A triple node sampling procedure was performed until
February 1988 (Du Toit et al, 1990). Nodes were sampled from the
lower axilla, the apex of the axilla and the internal mammary
chain. The current policy for node staging at the Nottingham
Breast Unit is for axillary node sampling of four or more nodes.
Internal mammary node sampling is also performed for tumours
located in the medial part of the breast. In 1988, we published
details ofhistological risk factors associated with an increased risk
of local recurrence after breast conservation for breast cancer
(Locker et al, 1989). Since then, patients whose tumours displayed
such factors were recommended conversion to mastectomy.
Patients with in situ ductal carcinoma (DCIS) only were treated by
mastectomy or wide local excision. No patients with DCIS under-
went a nodal staging procedure or received adjuvant radiotherapy.
Histopathology
Tumour size (cm) and lymph node stage (A, B or C) were known
for all patients with invasive breast cancer. The stratification of
lymph node stage for patients who underwent triple node biopsy
depends on the level ofaxillary node involvement and/or involve-
ment of the internal mammary chain and has been previously
reported by our unit (Du Toit et al, 1990). Using our current
staging system, node-negative disease is stage A, involvement of
1-3 axillary nodes or involvement of the internal mammary node
chain is stage B and involvement offour or more axillary nodes or
involvement ofboth axillary and internal mammary nodes is stage
C. Histological tumour grade was determined using the method
described by Elston and Ellis (1991). Tumour type was assessed
using standard criteria (Page and Anderson, 1987; Ellis et al,
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1992). Vascular invasion (VI) was classified as definite only if
tumour cell emboli were noted within an endothelium-lined
vascular or lymphatic space (Pinder et al, 1994).
Previous studies from the Nottingham Breast Unit have shown
that invasive tumour size, histological grade and lymph node stage
are independent prognostic indicators for breast cancer specific
survival (Haybittle et al, 1982: Galea et al, 1992). These three
histological factors are used to determine the Nottingham
Prognostic Index (NPI), which identifies three different prognostic
groups (good prognostic group, GPG; moderate prognostic group,
MPG; poor prognostic group, PPG) in terms of breast cancer
specific survival. The NPI is based on actuarial survival data from
1664 patients aged < 70 years who received local and regional
treatment for primary operable invasive breast cancer < 5 cm in
size between 1973 and 1988. No patients received adjuvant
systemic therapy. Patients with in situ breast cancer are excluded
from analyses usi-ng the NPI. The NPI is calculated using the
following equation: NPI = 0.2 x tumour size (cm) + grade (1-3) +
lymph node score (1-3 according to stage A-C). A score of < 3.4
gives a good prognosis, 3.41-5.4 a moderate prognosis and > 5.4 a
poor prognosis.
The NPI was calculated for all patients with invasive breast
cancer in all three age groups for this study.
Adjuvant systemic therapy
Patients were not routinely given adjuvant systemic therapy before
October 1988. Thereafter systemic therapy was given to all
patients with NPI > 5.4 (poor prognostic group). Our current
protocol is to offer adjuvant systemic therapy to all patients in the
medium and poor prognosis groups. Post-menopausal patients
with oestrogen receptor (ER)-positive tumours are treated with
tamoxifen for 5 years. Patients with ER-negative tumours are
offered chemotherapy using cyclophosphamide, methotrexate and
5-fluorouracil (CMF) for 6 months or tamoxifen for 5 years.
Premenopausal patients with ER-negative tumours are treated with
CMF for 6 months. Those with ER-positive tumours are offered
CMF for 6 months or randomization to the Zeneca Zebra Study
118630/2802 which compares CMF for 6 months with monthly
Zoladex injections for 2 years in premenopausal node-positive
breast cancer patient;. The number ofpatients who received adju-
vant systemic therapy according to age groups is shown in Table 1.
Survival
Patients were reviewed at 3-monthly intervals for 2 years,
6-monthly to 5 years and annually thereafter. Follow-up for this
group ofpatients was between 3 and 20 years. Survival curves for
metastasis disease-free interval and actuarial survival for the three
age groups were constructed using the life table analysis method
and differences between groups were calculated using the modifi-
cation of the Wilcoxon rank test (Lee Desu statistic) (Mantel,
1966). The prognostic significance ofage(< 35 years, 35-70 years)
was also assessed by being entered into a Cox multivariate model
(Cox, 1972) together with the known independent prognostic
discriminants invasive tumour size (< 2 cm, 2-5 cm), histological
tumour grade (1-3) and lymph node stage (A-C). The model of
best fit, which included all results of the variables being tested,
comprised 2630 cases (109 patients aged < 35 years, 2521 patients
aged 35-70 years). Parameters other than survival were compared
Table 1 Patients in both medium and poor prognostic groups receiving
adjuvant systemic therapy according to age groups and type of treatment
Age groups
Adjuvant < 35 years 35-50 years 51-70 years
therapy (n = 95) (n = 637) (n = 1054)
Chemotherapy (CMF) 14 (14.7%) 58 (9.1%) 8 (0.8%)
Endocrine therapy 0 34 (5.3%) 201 (19.1%)
using the standard X2 test. Significance was reached ifthe P-value
was < 0.05 for the statistical method used.
RESULTS
Surgical treatment
There was a difference in surgical management between.the three
age groups. Sixty-five of 120 patients (54%) in age group I under-
went breast conservation compared with 410 of 1003 (42%) in age
group I! and 421 of 1756 (24%) in age group III (X2=116.1,
P< 0.00001, 2 d.f.).
Histopathology
Differences in histological variables are summarized in Tables 2
and 3. Patients in age group I had a higher proportion of high-
grade ductal tumours and fewer lobular or low-grade well-differ-
entiated 'special type' tumours. A significant excess of medullary
and atypical medullary cancers were seen in age group I. There
was no difference in the proportion of patients with in situ ductal
cancer between age groups. Lymphatic-vascular invasion was
more frequently seen in age group I patients. No differences were
seen for tumour size and lymph node stage. Table 4 illustrates the
stratification of patients into the three Nottingham Prognostic
Groups according to age groups. Thirty-one per cent ofpatients in
age group I were of the poor prognostic group (PPG) compared
with 16% and 15% ofpatients in age groups II and III respectively.
This was reciprocated in the good prognostic group (GPG) which
comprised only 14% ofpatients in age group I compared with 32%
and 35% ofpatients in age groups II and III respectively.
Adjuvant therapy
There was no difference in the number of patients in age group I
who received any adjuvant systemic therapy compared with age
groups II (x2=.001 P=0.9, I d.f.) and III (X2=l.14 P=0.29, 1 d.f.).
Significantly more patients in age group I received cytotoxic
chemotherapy compared with patients in age group III (X2=83.37,
P< 0.00001, 1 d.f.). No difference was seen in patients who
received cytotoxic chemotherapy between age groups I and II
(X2=2.36, P=0.12, 1 d.f.).
Survival
Figures! and 2 illustrate metastasis disease-free survival and actu-
arial survival between age groups I (< 35 years), 11(35-50 years)
and III (51-70 years). Both metastasis disease-free survival and
actuarial survival in age group I were significantly less than that of
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Table 2 Characteristics of invasive cancers according to age at diagnosis (d.f., degrees of freedom)
Histological Variables < 35 years 35-50 years 51-70 years P2-value
characteristic (n=111) (%) (n=941) (%) (n=1623) (%)
Invasive tumour size
<2 cm 45 (41) 401 (43) 758 (47) 5.18 0.08
2-5 cm 66 (59) 540 (57) 865 (53) (2 d.f.)
Tumour grade
7 (6) 193 (21) 345 (21) 58.55 <0.0005
11 20 (18) 299 (32) 615 (38) (4 d.f.)
III 84 (76) 449 (47) 663 (41)
Lymph node stage
A 62 (56) 599 (64) 1045 (64) 5.41 0.25
B 31 (28) 240 (26) 382 (24) (4 d.f.)
C 18 (16) 102 (10) 196 (12)
Lymphatic-vascular
invasion (VI)
Absent 72 (65) 676 (72) 1282 (78) 30.39 0.0005
Present 39(35) 265(28) 341 (21) (2 d.f.)
Table 3 Differences in tumour type according to age at diagnosis. NST, no special type; DCIS, ductal carcinoma in situ. aAtypical medullary.
Tumour type < 35 years 35-50 years 51-70 years X-2value
(%) (%) (%) (2 d.f.)
NST 80 (67) 535 (53) 923 (53) 8.98 0.01
Special type 7 (6) 225 (23) 377 (21) 17.96 0.0001
Medullary/atypicala 16 (12) 64 (6) 68 (4) 25.47 < 0.0001
Lobular 8 (8) 117 (12) 255 (14) 9.21 < 0.01
DCIS 9 (7) 62 (6) 133 (8) 1.91 0.38
Total 120 1003 1756
Table 4 Patients with invasive breast cancer stratified according to Nottingham Prognostic Groups and age at
diagnosis (X2 = 31.5, P<0.00001, 4 d.f.).
Age groups
NPI score Nottingham prognostic < 35 years 35-50 years 51-70 years
group (%) (%) (%)
< 3.4 Good 16 (14) 304 (32) 569 (35)
3.4-5.4 Moderate 61 (55) 494 (52) 814 (50)
>5.4 Poor 34 (31) 143 (16) 240 (15)
Total 111 941 1623
age groups II and III at 15 years follow-up. The result for actuarial
survival ofthe Cox multivariate model using < 35 years as the cut-
off for age of onset is shown in Table 5. Invasive tumour size,
histological grade and lymph node stage continued to be strong
independent prognostic discriminants for breast cancer specific
survival. Age < 35 years was not an independent prognostic factor.
After subdividing patients into three groups (good, medium and
poor) according to the Nottingham Prognostic Index, no survival
differences were seen according to age within each prognostic
group. When the survival curves according to NPI were plotted for
all patients, no differences were illustrated when the survival
curves ofwomen aged < 35 years were plotted alongside (Figure 3).
DISCUSSION
Breast cancer diagnosed at an early age is not common. In this
series, only 4% of patients with primary operable breast cancer
aged < 70 years were < 35 years at the time of diagnosis. In large
population-based Scandinavian studies by Host and Lund (1986)
and Adami et al (1986), patients with breast cancer diagnosed < 35
years accounted for < 2% of all patients. In this series, the ratio of
109 patients aged 25-34 with invasive breast cancer against 1623
aged 51-70 allows an approximation of the incidence of primary
breast cancer in the young age group. In the UK, the incidence of
invasive breast cancer in women aged 51-70 years is 17 per 10000
British JournalofCancer(1997) 75(9), 1318-1323 .Cancer Research Campaign 1997Early onsetbreastcancer 1321
Table 5 Cox multivariate analysis for invasive tumour size, histological grade, lymph node stage and age of
onset. J, regression coefficient; RR, relative risk; Cl, confidence interval.
Variable ,B-Value RR 95% Cl P-value
Invasive tumour size (<2 cm, 2-5 cm) -0.187 0.83 0.77-0.89 < 0.00001
Histological grade (1, 2, 3) 0.789 2.20 1.96-2.47 < 0.00001
Lymph node stage (A, B, C) 0.868 2.40 2.18-2.60 < 0.00001
Age of onset (<35, 35-70 years) -0.027 0.97 0.83-1.15 0.75
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Figure 1 Metastasis disease-free survival curves for age group (*, age
<35 years), group 11 (O, age 35-50 years) and group III (A, age 51-70
years). X2 = 9.32. P= 0.01 (2 d.f.)
-U
.2.
ir a)
E
0
No at risk
Group
Group II
Group IlIl
1001
90
80
70
60
50
4A
0 24 48 72 96 120 144 168
Time (months)
192
120 107 70 49 32 22 15 11 8
1003 920 646 459 322 218 157 96 59
1756 1622 1138 762 479 320 205 116 65
Figure 2 Actuarial survival curves for age group (*, age < 35 years), group
11 (Ol, age 35-50 years) and group III (A, age 51-70 years). %2 = 6.6.
P = 0.03 (2 d.f.)
per annum (Forrest, 1987). This means that the average incidence
of breast cancer between ages 25 and 34 in this series is 1.1 per
10000 per annum.
Several studies have shown that early age at diagnosis is associ-
ated with histological tumour characteristics, suggesting an
aggressive breast cancer phenotype (Earley et al, 1969; Wallgren
et al, 1977; Rosen et al, 1984; Remvikos et al, 1995). In this series,
patients diagnosed with breast cancer at age < 35 years were more
likely to have high-grade tumours exhibiting vascular invasion.
48 72 96 120 144 168 192
Time (months)
Figure 3 Actuarial survival of patients according to Nottingham Prognostic
Index and age. v-*, GPG for all patients (n = 891); 0-----0, GPG for
patient age < 35 years (n = 16); A-A, MPG for all ages (n = 1369); A-----A,
MPG for patient age < 35 years (n = 61); -, PPG for all ages (n = 415);
l-----l, PPG for patient age < 35 years (n = 34). Within any one NPI group,
no difference is seen according to age
The young age group were less likely to have lobular carci-
nomas or well-differentiated 'special type' cancers, which are
associated with a survival advantage compared with ductal carci-
nomas of no special type (Ellis et al, 1992). Several studies have
suggested that medullary and atypical medullary carcinomas are
more common in young patients (Gogas and Skalkeas, 1975;
Rosen et al, 1985; Claus et al, 1993). This also occurred in our
series. An excess proportion of medullary and atypical medullary
cancers has recently been reported in young women with BRCAl-
related hereditary breast cancer (Marcus et al, 1996). The associa-
tion of these two tumour types in patients with sporadic
early-onset breast cancer could denote the presence of a breast
cancer susceptibility gene mutation. Although it has been
suggested that medullary carcinoma carries a good prognosis
(Ridolfi et al, 1977), we have previously reported that neither
medullary carcinoma nor atypical medullary carcinoma have a
survival advantage overductal carcinomas ofno special type (Ellis
et al, 1992).
Rosen et al (1984) found 8% of patients diagnosed with breast
cancer at age < 35 years to have in situ disease. In this series, 8%
ofcancers diagnosed in women aged < 35 years were non-invasive.
However, the percentage ofpatients with DCIS was similar within
the three age groups (6-8%).
Tumour size did not differ between age groups in this series. No
differences in lymph node status were demonstrated between
age groups. These findings are similar to those of other series
which showed no differences in lymph node involvement between
young patients and older age groups (Mueller et al, 1978; Rosen
et al, 1984).
Age at diagnosis as a prognostic indicator in breast cancer has
been considered in several publications. Large epidemiological
studies based on tumour registries (Adami et al, 1986; Host and
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Lund, 1986; Sant et al, 1991) and clinical studies (Earley et al,
1969; Noyes et al, 1982; Ries et al, 1991; De La Rochefordiere
et al, 1993; Bonnier et al, 1995) have shown early age at diagnosis
to be an adverse factor affecting prognosis. Others have shown no
survival difference between age groups (Birks et al, 1973; Gogas
and Skalkeas, 1975; Wallgren et al, 1977; Rosen et al, 1984;
Backhouse et al, 1987; Barchielli et al, 1994). The results of this
study using a large patient cohort with long-term follow-up have
shown a significant difference in metastasis disease-free survival
and actuarial survival between young breast cancer patients and
two older age groups with primary operable invasive breast cancer.
This is entirely explained by a significantly higher proportion of
young patients having biological tumour characteristics, such as
high grade and vascular invasion, which are associated with a
worse prognosis (Elston and Ellis, 1991; Pinder et al, 1994). This
results in more young patients lying within the poor prognostic
group. No differences were seen when survival between age
groups was compared according to the three Nottingham prog-
nostic groups. Survival in young breast cancer patients was exactly
as predicted by their prognostic index. This was confirmed by the
results of the Cox multivariate analysis which failed to demon-
strate young age as an independent prognostic indicator when
compared to the three histological factors that comprise the NPI.
The results of this study differ from those of a recent study by
Bonnier et al (1995) which suggested that young age was
an independent prognostic indicator after using a Cox model.
Discrepancies in the results ofthe two studies may be explained by
the small number ofearly-onset cases used to fit the Cox model in
Bonnier's study, which may not be representative ofthe group as a
whole. Furthermore, the Bloom and Richardson histological
grading system used in that study is often criticized for being too
subjective. Because histological tumour grading is a strong prog-
nostic indicator, inconsistencies in a grading system will have a
marked effect on other factors used in a multivariate analysis. The
semiquantitative grading system proposed by Elston and Ellis
(1991) has been shown by other centres to be reproducible with
little interobserver variability (Dalton et al, 1994; Cummings et al,
1995; Frierson et al, 1995).
No differences were seen in the proportion of patients in the
moderate and poor prognosis groups who received adjuvant
systemic therapy according to age groups. Therefore, the effect of
adjuvant systemic therapy is not expected to contribute to the
differences seen in actuarial survival.
Young age alone is not an independent prognostic variable in
primary breast cancer. However, adverse intrinsic biological factors
are more likely to be found in breast cancers ofyoung women.
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